These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23429779)

  • 1. Effects of pregabalin on behavioral alterations induced by ketamine in rats.
    Nunes EA; Canever L; Oliveira Ld; Luca RD; Quevedo J; Zugno A; Peregrino A; Crippa JA; Dursun SM; Baker GB; Hallak JE
    Braz J Psychiatry; 2012 Oct; 34(3):329-33. PubMed ID: 23429779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats.
    Imre G; Fokkema DS; Ter Horst GJ
    Eur J Pharmacol; 2006 Aug; 544(1-3):77-81. PubMed ID: 16860791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketamine on prepubertal Wistar rats: Implications on behavioral parameters for Childhood-Onset Schizophrenia.
    Damazio Pacheco F; Canever L; Antunes Mastella G; Gomes Wessler P; Kunz Godoi A; Hubbe I; da Costa Afonso A; Celso D; Quevedo J; Ioppi Zugno A
    Int J Dev Neurosci; 2019 Dec; 79():49-53. PubMed ID: 31678549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of posterior cingulate cortex in ketamine-induced psychosis relevant behaviors in rats.
    Ma J; Leung LS
    Behav Brain Res; 2018 Feb; 338():17-27. PubMed ID: 28993219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.
    Becker A; Grecksch G
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1267-77. PubMed ID: 15588753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketamine in normal and schizophrenic volunteers.
    Lahti AC; Weiler MA; Tamara Michaelidis BA; Parwani A; Tamminga CA
    Neuropsychopharmacology; 2001 Oct; 25(4):455-67. PubMed ID: 11557159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.
    Duncan GE; Miyamoto S; Leipzig JN; Lieberman JA
    Brain Res; 1999 Oct; 843(1-2):171-83. PubMed ID: 10528123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors.
    Hołuj M; Popik P; Nikiforuk A
    Behav Pharmacol; 2015 Dec; 26(8 Spec No):766-75. PubMed ID: 25769091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurotensine dipeptide analog dilept decreases the deficiency of prestimulus startle reflex inhibition: a prognostic sign of antipsychotic activity].
    Ostrovskaia RU; Krupina NA; Gudasheva TA; Voronina TA; Seredenin SB
    Eksp Klin Farmakol; 2009; 72(5):3-7. PubMed ID: 19928566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia.
    Heylmann ASA; Canever L; Gress K; Gomes ST; Fachim I; Michels C; Stopassoli GC; Mastella GA; Steckert AV; Damiani AP; de Andrade VM; Quevedo J; Zugno AI
    Behav Brain Res; 2017 May; 326():154-164. PubMed ID: 28286284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates.
    Shiigi Y; Casey DE
    Psychopharmacology (Berl); 1999 Sep; 146(1):67-72. PubMed ID: 10485966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.
    Zugno AI; Julião RF; Budni J; Volpato AM; Fraga DB; Pacheco FD; Deroza PF; Luca RD; de Oliveira MB; Heylmann AS; Quevedo J
    Metab Brain Dis; 2013 Sep; 28(3):501-8. PubMed ID: 23775300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice.
    Jeevakumar V; Driskill C; Paine A; Sobhanian M; Vakil H; Morris B; Ramos J; Kroener S
    Behav Brain Res; 2015 Apr; 282():165-75. PubMed ID: 25591475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens.
    Razoux F; Garcia R; Léna I
    Neuropsychopharmacology; 2007 Mar; 32(3):719-27. PubMed ID: 16525415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats.
    Ma J; Leung LS
    Psychopharmacology (Berl); 2007 May; 191(4):961-74. PubMed ID: 17219218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Receptor antagonist of NMDA and animal models of schizophrenia].
    Bian SZ; Zhang J; Liu WL; Sun ZH; Gu ZL; Jiang XG
    Fa Yi Xue Za Zhi; 2009 Dec; 25(6):443-6. PubMed ID: 20225623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
    Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.
    Duncan GE; Leipzig JN; Mailman RB; Lieberman JA
    Brain Res; 1998 Nov; 812(1-2):65-75. PubMed ID: 9813244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats.
    Zoupa E; Gravanis A; Pitsikas N
    Neuropharmacology; 2019 Jun; 151():74-83. PubMed ID: 30959020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.